-transparent.png){kind=logo}
The combination of cis-platinum (DDP), adriamycin, and 5-fluorouracil was evaluated in 44 patients with advanced urothelial cancer, 39 of whom were evaluable for response. There were 18 partial remissions (46.2%) and no complete responses. Remissions were clinically meaningful, but of short duration. Four patients had bulky pelvic disease that was made resectable by chemotherapy, but none of these patients remained disease-free. These results are not superior to that expected from DDP as a single agent. In addition, there appears to be little or no survival benefit associated with chemotherapy. DDP represents an advance in the treatment of bladder cancer, but additional active agents and innovative approaches are needed.
S D Williams, and
L H Einhorn, and
J P Donohue
December 1990,
Journal of chemotherapy (Florence, Italy),
S D Williams, and
L H Einhorn, and
J P Donohue
June 1987,
Gan to kagaku ryoho. Cancer & chemotherapy,
S D Williams, and
L H Einhorn, and
J P Donohue
September 1985,
Gan no rinsho. Japan journal of cancer clinics,
S D Williams, and
L H Einhorn, and
J P Donohue
July 1998,
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
S D Williams, and
L H Einhorn, and
J P Donohue
January 1982,
Cancer chemotherapy and pharmacology,
S D Williams, and
L H Einhorn, and
J P Donohue
January 1986,
Harefuah,
S D Williams, and
L H Einhorn, and
J P Donohue
January 1985,
Cahiers d'anesthesiologie,
S D Williams, and
L H Einhorn, and
J P Donohue
January 1979,
Transactions of the American Association of Genito-Urinary Surgeons,
S D Williams, and
L H Einhorn, and
J P Donohue
August 1983,
The Australian and New Zealand journal of surgery,
S D Williams, and
L H Einhorn, and
J P Donohue
September 1984,
British journal of obstetrics and gynaecology,
